What are the contraindications of octreotide (somatostatin analogue)?

Contraindications of Octreotide

Octreotide is contraindicated in patients with hypersensitivity to the drug or any of its components. 1

Primary Contraindications

• Hypersensitivity: Octreotide should not be used in patients with known sensitivity to this drug or any of its components 1

• Insulinoma: Octreotide should be used with extreme caution or avoided in patients with insulinoma, as it can worsen hypoglycemia by suppressing counterregulatory hormones such as growth hormone, glucagon, and catecholamines 2, 3, 4

• Somatostatin receptor-negative tumors: Octreotide should only be administered to patients whose tumors are somatostatin scintography-positive 2

Relative Contraindications and Special Precautions

Cardiac Considerations

• Use with caution in patients with:

  • Cardiac conduction abnormalities
  • History of bradycardia or arrhythmias
  • At-risk cardiac patients 1

• Increased risk for higher degree of atrioventricular blocks

• Consider cardiac monitoring in patients receiving octreotide intravenously 1

Metabolic Considerations

• Glucose metabolism disorders: Careful monitoring required as octreotide can cause:

  • Hypoglycemia
  • Hyperglycemia
  • Glucose monitoring is recommended and anti-diabetic treatment may need adjustment 1

• Thyroid function: Monitor thyroid levels periodically as hypothyroidism may occur 1

Gastrointestinal Considerations

• Cholelithiasis: Monitor periodically for gallbladder abnormalities
• Discontinue if complications of cholelithiasis are suspected 1

Drug Interactions Requiring Special Attention

The following medications require monitoring and possible dose adjustment when used with octreotide:

• Cyclosporine

• Insulin

• Oral hypoglycemic agents

• Beta-blockers

• Bromocriptine 1

• Lutetium Lu 177 Dotatate Injection: Discontinue octreotide at least 24 hours prior to each lutetium Lu 177 dotatate dose 1

Special Populations

Pregnancy and Breastfeeding

• Advise premenopausal females of the potential for an unintended pregnancy 1

Nuclear Medicine Imaging Considerations

• For optimal imaging results:
  • Short-acting somatostatin analogues should be withdrawn for 24-48 hours before imaging
  • For long-acting analogues, schedule imaging toward the end of the dosing interval 3

Common Pitfalls and Caveats

1. Insulinoma management: The most critical contraindication to remember is in patients with insulinoma, where octreotide can precipitously worsen hypoglycemia and potentially lead to fatal complications 2

2. Somatostatin receptor status: Always verify somatostatin receptor positivity before initiating treatment, as octreotide is ineffective in receptor-negative tumors 2

3. Monitoring requirements: Regular monitoring of glucose levels, thyroid function, and gallbladder status is essential during octreotide therapy 1

4. Drug interactions: Be vigilant about potential interactions with commonly used medications, especially in diabetic patients on insulin or oral hypoglycemic agents 1

5. Cardiac effects: Remember that octreotide can cause bradycardia and conduction abnormalities, requiring careful monitoring in at-risk patients 1